methylprednisolone atseponat, Urea |

Release form

Cream for external use.



packaging 30 g tube

Pharmacological action

Anti-inflammatory and keratolytic drug for external use.

Indications

Inflammatory skin diseases that are sensitive to therapy with topical glucocorticosteroids and accompanied by impaired keratinization:

- atopic dermatitis, neurodermatitis

- true eczema

- dermatological contact (microbial eczema

d dermatitis - simple contact)

Contraindications

- hypersensitivity to the components of the drug

- tuberculosis or syphilitic processes in the area of ​​application of the drug

- viral diseases (e.g. chickenpox, shingles)

- rosacea, perioral dermatitis in the area of ​​application of the

preparation - patches of skin with manifestations of a reaction to

vaccination - children under 18 years of age

Special instructions

In the presence of bacterial complications and / or dermatomycosis, specific antibacterial and / or antifungal treatment is necessary in addition to Comfoderm® M2 therapy.

The drug is not intended for use in ophthalmology. Avoid contact with eyes and mucous membranes. As with systemic glucocorticoids, external use of corticosteroids can develop glaucoma (for example, after application in high doses, due to very long-term use, the use of occlusive dressings or application to the skin around the eyes). On the skin of the face more often than on other surfaces of the body, after prolonged treatment with corticosteroids for external use, atrophic changes can develop.

Influence on ability to drive vehicles and control mechanisms

Not identified.

Composition

100 g of cream contains:

Active substances: methylprednisolone aceponate 100 mg urea 2 g

Excipients: liquid paraffin (liquid paraffin) - 15 g, propylene glycol - 5 g, polysorbate 80 - 1 g, ka ribomer interpolymer (type A) - 1 g, trometamol - 400 mg, methyl parahydroxybenzoate - 100 mg, purified water - up to 100 g.

Dosage and Administration

Externally.

The drug is applied 1 time / day with a thin layer on the affected skin. As a rule, the duration of continuous daily treatment with ComfodermΠM2 should not exceed 12 weeks. In the treatment of patients with facial skin lesions, the course of treatment should not exceed 5 days.

Side effects

Very rarely (in less than 0.01% of cases) local reactions such as pruritus, burning, erythema, and the formation of a vesicular rash can be observed.

If the drug is used for more than 4 weeks and / or on an area of ​​10% or more of the body surface, the following reactions may occur: atrophy of the skin, telangiectasia, striae, acneform changes in the skin, systemic effects due to absorption of the corticosteroid.

In rare cases (0.01% -0.1%), folliculitis, hypertrichosis, perioral dermatitis, skin depigmentation, allergic reactions to one of the components of the drug can be observed.

Drug interaction

No drug interaction with other drugs has been identified, however, it should be borne in mind that the simultaneous use of the Comfoderm® M2 drug with other ointments or creams can lead to increased resorption of the drugs contained in them.

Overdose of

Symptoms: with excessively long and / or intensive local use of corticosteroids, skin atrophy may develop (thinning of the skin, telangiectasia, stria).

Treatment: if signs of skin atrophy appear, the drug must be discontinued.

Storage Conditions

The product should be stored out of the reach of children at a temperature not exceeding 25 РC.

Expiration

2 years.

ka from drugstore

Without prescription

lekarstvennaja form

cream

Akrikhin HFO AO, Russia